News Daily News High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk Michael O'Riordan July 01, 2019
News Conference News EAS 2019 Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role Michael O'Riordan June 07, 2019
News Conference News EAS 2019 Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality Michael O'Riordan June 05, 2019
News Conference News EAS 2019 Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION Michael O'Riordan June 04, 2019
News Conference News SCAI 2019 LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER Yael L. Maxwell June 03, 2019
News Conference News EAS 2019 Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients Michael O'Riordan May 30, 2019
News Conference News EAS 2019 CHD Mortality Significantly Elevated in Patients With Severe FH Michael O'Riordan May 29, 2019
News Conference News EAS 2019 Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis Michael O'Riordan May 28, 2019
News Daily News Familial Hypercholesterolemia Seen in 10% of Young MI Patients Michael O'Riordan May 15, 2019
News Daily News PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction Michael O'Riordan April 29, 2019
News Conference News ACC 2019 Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom Michael O'Riordan March 20, 2019
News Daily News Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony Michael O'Riordan March 15, 2019
News Daily News Could PET Imaging Be the ‘Game Changer’ for Detecting and Predicting Bioprosthetic Valve Degeneration? Michael O'Riordan March 13, 2019
News Conference News ACC 2019 ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend Shelley Wood March 11, 2019
News Daily News Alirocumab Price Cut Makes Second PCSK9 Inhibitor More Affordable Shelley Wood February 12, 2019
News Features Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis? Michael O'Riordan February 01, 2019
News Daily News AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline Michael O'Riordan January 29, 2019
Presentation Controversies and Advances 2018 Updateon PCS K-9 Inhibition Presenter: P.K. Shah November 15, 2018